|
Home / Finance
Could ViRexx Medical’s ‘Linked Recognition’ Research Lead to a Cancer Vaccine?
By:
While preparing a lecture in biochemistry and virology for his graduate students at the University of Alberta in the early 1980s, Dr. Lorne Tyrrell ran across a study just published in the medical journal, Cell. The research by William Mason and Jesse Summers, entitled “Replication of Hepatitis B,” discussed their study of the hepatitis B virus in infected duck liver.
A SCIENTIST’S 20-YEAR UNFINISHED JOURNEY TO TREAT HBV MAY OPEN THE DOOR TO A NEW CLASS OF FLEXIBLE VACCINES
After studying their duck model theory, Tyrrell speculated if the hepatitis B virus (HBV) might be susceptible to antiviral agents, and consulted with a colleague, who specialized in nucleoside chemistry. Both medical professors became excited about the possibility of inhibiting the HBV virus with nucleoside analogues. Thus began the infectious disease specialist’s first leg of a journey, which led to the use of lamivudine as a therapy for chronic HBV infections.
More than 350 million people across the world, especially in Asia, now had new hope, some for their lifelong infections contracted vertically at birth from their mothers. In 2003, the Center for Disease Control estimated 73,000 Americans were infected with HBV, and about 5,000 die each year from sickness caused by HBV. It is reportedly 100 times more contagious than the AIDS virus. Many in North America, who had been infected with the virus from sexual transmission or intravenous drug use, were offered a potentially life-saving therapy.
Licensed in 1998, lamivudine is now used in 120 countries as a standard therapy for chronic HBV carriers. The compound is also used in combination with other drugs, such as protease inhibitors, for HIV therapy. Development rights were licensed to Glaxo Wellcome in 1990, which is now sold under the brand name Epivir®. For his pioneering efforts in developing the antiviral agent, Dr. Tyrrell was awarded the gold medal by the Canadian Liver Foundation and the Canadian Association for the Study of Liver in 2000. In 2005, he won the prestigious EnCana Principal Award for his development of the first effective oral medication for Hepatitis B.
HIS UNANSWERED QUESTIONS LAUNCHED A NEW HBV INVESTIGATION
Despite the awards and recognition, questions remained for Dr. Tyrrell about the shortcomings of lamivudine. He was troubled that some viruses would develop resistance to the compound. “I was disappointed the sustained viral response was not complete,” Tyrrell told us. In April 2003, the Journal of Antimicrobial Chemotherapy published a study in Japan showing, “long-term (lamivudine) therapy is associated with increased emergence of lamivudine-resistant strains of HBV.” Researchers concluded in this study, “The therapeutic challenge to effectively treat chronic HBV infection continues.”
Having screened lamivudine for use in Hepatitis B at Glaxo’s research lab at the University of Alberta, Dr. Tyrrell was able to observe the immune response of various HBV patients. “What really got me interested in doing more work in this area was that we noticed patients, who have an immune response to the virus and take lamivudine, will have a better sustained response rate,” Tyrrell explained. “A patient with elevated liver transaminases taking lamivudine had a higher probability of a sustained viral response,” Tyrrell said with excitement in his voice. “In a patient with normal liver enzymes, who gets lamivudine, the virus will go down, but as soon as you stop the therapy, the virus comes right back up.” He told us the sustained viral response is only about two to three percent. Only about 30 percent remain free of the virus, about one year after patients have stopped taking lamivudine.
“How do you break tolerance?” Tyrrell asked himself, hoping to develop a way to stimulate an immune response. All of the patients, he had observed, seemed to be tolerant of the hepatitis B virus. He pondered the dilemma, “Was there some way to break tolerance to hepatitis B by stimulating the immune response?” Tyrrell studied what others were attempting and wasn’t satisfied with the approaches others were taking to stimulate immune response. His ViRexx Medical research team brainstormed about different ways to target the antigen into the dendritic cells.
“That’s where we came in with the Chimigen™ technology,” Tyrrell said. “The dendritic cells have receptors on their surface that will bind the Fc portion of an antibody.” He pointed out a key feature of the Chimigen™ platform, “We used the Fc portion of a murine (mouse) antibody to hook onto our hepatitis B antigens. This would direct the viral antigens into dendritic cells in vivo.” Because the dendritic cells are the sentries of the immune system, they guard what comes in. Recognizing a ‘foreign situation’ in the murine antibody, it treats the whole molecule including the virus antigen as foreign.
LINK RECOGNITION MAY HOLD THE KEY
Dr. Rajan George, ViRexx Medical’s vice president of research and development, told us, “The dendritic cells chop up this protein into small pieces called peptides, also known as epitopes. The dendritic cells have a system where they put the T-cell epitope on another protein, MHC Class I, and bring it to the surface of the dendritic cell. They are presented as a complex on the surface of the dendritic cell to attract the T-cells.” When the T-cells arrive to inspect the foreign entity, the cytotoxic T-cells are activated. Then, they begin attacking and killing the virus-infected cells.
Research at Tokyo’s Cancer Institute Hospital, published in 1987 in Nippon Sanka Fujinka Gakkai Zasshi, suggested a feasibility of linked recognition of a virus antigen as a helper in tumor immunity with a target antigen. In the case of ViRexx Medical, Tyrrell’s team has created a new molecule, called “chimigen.” The term is shorthand for a chimeric antigen, meaning it is an antigen created from two different sources, part virus and part murine monoclonal antibody.
Dr. Tyrrell’s work at ViRexx Medical with Dr. George suggested the linked-recognition theory might be the key to breaking tolerance. Dr. George emphasized, “The new ‘chimigen’ stimulates an immune response to the antigen as well as the viral antigen. This is very important because the virus antigen was previously being ignored.” That brings us back to why lamivudine had limited success. The immune systems of some HBV carriers failed to recognize the viral infection as a threat to the body. Tyrell’s ViRexx Medical research team hopes the body’s immune system sees the threat, thus stimulating the immune system, and breaking tolerance. It appears Dr. Tyrell may soon find out whether or not the questions he asked will bring the answers he hoped for.
END OF PART ONE
Digg
del.icio.us
Blink
Stumble
Spurl
Reddit
Netscape
Furl
Article keywords: Cancer, hepatitis, hepatitis b, infections, disease, immune system, HBV, HIV, virus, medical, HCV
Article Source: http://www.articles2k.com
James Finch contributes to StockInterview.com and other publications. Visit http://www.stockinterview.com to read more articles by James Finch. Write to James Finch at jfinch@stockinterview.com
|
|
| Top Finance Articles |
- 1). Locate And Find Debtors With A Credit Collection Agency By : Stu Pearson
It can be a frustrating experience trying to collect a debt from a customer who just seems unwilling to pay. Letters sent to their address go ignored, and phone calls are answered with empty promises of payment. While this is certainly a bad scenario, what if a customer who owes you money just disappears? It is possible to locate and find debtors with a credit collection agency, and in this article we’ll explain to you the methods behind their tracking.
|
|
|
|
|
- 4). Who Is Responsible For Closing Costs By : Raynor
Buying or selling a home is a euphoric experience for both of the parties involved. This euphoria can cool when you learn which party is responsible for the closing costs.
Who Is Responsible For Closing Costs
When looking to buy or sell a home, every person eventually arrives at the question of funding closing costs on the transaction. To put it simply, both buyers and sellers typically are responsible for some of the closing costs.
|
- 5). Family Finance By : Joseph Kenny
One of the hardest things that young couples report during their first year of marriage is getting to grips with joint finances. While most are willing to share what they have with their partner, they are not sure on the best way to bring this sharing into effect so that they can share with their new partner, but at the same time maintain financial security and a degree of independence.
|
- 6). Preparing Your Finances For A Bird Flu Pandemic By : Pandemic Zone
If you have been paying attention to the news lately you may of heard of the threat of bird flu and a world pandemic. What would this mean and how would it affect your financial holdings. The World Bank, which has estimated that a bird flu pandemic lasting a year could, cost the global economy up to $800 billion dollars. The economic toll on the world economy will be catastrophic.
|
|
|
- 8). High Gas Prices and Ways to Save By : essmeier
With Memorial Day around the corner, the great American travel season is here. During the summer, most Americans take at least one extended vacation, and four fifths take that trip by automobile. Unfortunately, this year, the price of gas is at record highs, and no one likes to spend their vacation money on gasoline. While there is little to be done about the price of gas itself, there are some things the average vacationer can do to help ease the costs of auto travel.
|
|
|
|
|
| New Finance Articles |
- 1). How To Earn Money Online In Five Easy Steps By : John Morris
Living in Los Angeles, Greg realized that there are a lot of people who work from home rather than the office. One reason is that many of these executives are writers and producers of films and television shows...
|
- 2). You Can Stick to Your Budget By : Jonathon Hardcastle
Recent studies have shown that Americans are spending less money on necessities than ever before. Yet, more Americans are also in debt. The unspoken fact that makes both those statements true is that Americans are spending more and more money on luxury items.
|
- 3). Technical Analysis Of Stock Data By : John Morris
To perform a technical analysis is simply examining stock chart data in order to make predictions about the future of that stock. Investors who use this style of analysis are often unconcerned about the nature or value of the companies they trade stocks in...
|
- 4). Getting The Most Money Out Of Selling Your House By : John Morris
It is easier said than done to make a profit in the real estate market nowadays. Those that manage to consistently turn a profit on real estate investments have been working in that field for years and are using proven strategies in order to minimize risk...
|
|
|
|
|
|
|
|
|
|
|
- 10). How Can I Be Approved For A Low Rate Credit Card? By : Mike Singh
When applying for a credit card you may come upon what is called a low rate credit card, what is this exactly and how can it help you? First of all you should know that a low rate credit card is usually an excellent way to go when applying for a credit card. Find out more...
|
|
|
